A Multicentre, Retrospective-prospective Real-world Study: to Evaluate the Effectiveness and Safety of Vorasidenib in Patients With Isocitrate Dehydrogenase IDH1/2 Mutant Grade 2 Astrocytoma or Oligodendroglioma (VICTORIA Study)

NCT06969352 · clinicaltrials.gov ↗
NOT_YET_RECRUITING
Status
60
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Servier (Tianjin) Pharmaceutical Co. LTD.

Collaborators